Do you want to develop a monoclonal antibody conserving its native properties with maximized developability? Our single B-cell sorting service provides highly affine antibodies with natural VH and VL pairing and maximum B-cell diversity. We guarantee you receive a minimum of 3 antibody sequences within a maximum of 2 months from animal immunization to antibody screening thanks to our high throughput single B-cell antibody technologies platform.
3 binders guaranteed
We guarantee at least 3 binders to your antigen of interest
Maximized developability
We make sure you get antibodies with the best physicochemical characteristics to get maximum developability
High throughput screening
Our screening method allows you to perform different screening in a highly efficient manner
Native monoclonal antibody
We guarantee a VL and VH natural pairing
Maximum diversity
Our single B-cell antibody technologies generates a high repertoire of antibodies thus preserving B cell natural diversity
Pay only if satisfied
If you get 3 binders, pay 100%. If no binders, we charge minimal fees only
Market’s leading Antibody solution
Benefit from our system optimized for high yields and high-throughput antibody production
Your antibody in 2 months
Get your antibody sequence within 2 months for the whole process including animal immunization
IP free
Be the owner of the antibody sequences that we generate for you
Immunization
4-6 weeks
Single B-cell sorting and screening
2-3 weeks
Recombinant rabbit antibody (IgG) production and screening
2 weeks
Want to test additional ELISA?
ProteoGenix’s B cell sorting services offer a flexible and customizable pricing structure to cater to your individual needs. Our prices start at a few thousand euros with pricing depending on the number of specific requirements for each project. The pricing is largely influenced by the number of antibody sequences to be analyzed and the scope of the service purchased.
We also offer the option for customers to enhance their single B cell sorting experience with supplementary services. These additional services include ELISA for positive/negative screening against specific peptides, proteins, or small molecules, as well as cross-reactivity profiling. Furthermore, our Competitive ELISA service enables the identification of clones with blocking or neutralizing activity, providing invaluable insights for therapeutic development.
Building a custom antibody using B cell isolation is a valuable investment that yields long-term cost savings. By precisely selecting high-affinity antibody clones early in the development process, it minimizes resources spent on less promising candidates. The targeted approach reduces downstream costs, ensuring efficient large-scale production and accelerating the path to a successful therapeutic, resulting in substantial savings in the long run.
At ProteoGenix, we understand the uniqueness of each project and aim to provide tailored solutions for our clients. Our team of experts works closely with customers to evaluate their specific needs and propose the most appropriate services within their budget. With our transparent and ranking-based pricing approach, customers can confidently choose the services that best align with their research objectives, ultimately ensuring the success of their single B cell sorting projects.
At ProteoGenix, our single B cell antibody technologies are designed for rapid and efficient results. The customer can get his antibody within only 8 weeks, ensuring a quick turnaround for their project.
We are proud to introduce our new immunization protocol that offers significant time savings, allowing us to complete the process 50% faster than our competitors. Immunization delays have been reduced from the typical 6-8 weeks to just 4-6 weeks, further streamlining the B cell sorting timeline and providing customers with even faster access to their desired antibody sequences.
You can patent your antibody sequence that is delivered from our B cell sorting service. We believe in providing our customers with full ownership of their antibody sequences, giving you the freedom and protection to secure intellectual property rights for your valuable discoveries.
With our B cell sorting services, you can confidently pursue patent applications and protect the innovative potential of your custom antibodies, ensuring their exclusivity and commercial value in the market.
Single B-cell sequencing is an efficient monoclonal antibody development and screening strategy whose principle is based on the amplification of genes encoding the VH and VL region from B-cells directly. This technology presents several advantages making it a very useful approach for antibody biology understanding and for antibody use in clinical essays. Among these advantages, single B-cell sorting is characterized by:
To date, several techniques have been developed to isolate and screen monoclonal antibodies (mAbs). This table summarizes the main advantages and drawbacks of each technique.
Single B cell isolation plays a vital role in diverse research and clinical applications, facilitating the isolation of pure B cell populations for in-depth studies.
Understanding immune responses, uncovering novel antibodies, and developing immunotherapies heavily rely on the precision and efficiency of this technique. By isolating specific B cell subsets, researchers gain valuable insights into immune system functioning, enabling advancements in vaccine development, autoimmune disease research, understanding immunodeficiencies, allergy research, infectious diseases, and cancer immunotherapy.
The ability to extract high-affinity antibodies directly from B cells expedites antibody discovery, accelerating the development of potential therapeutics. With its broad applications across immunology and medicine, single B cell antibody technologies stand as powerful tools, propelling breakthroughs in numerous disciplines.
B-cells are a type of white blood cell commonly called a B lymphocyte. They function by providing organisms with adaptive immunity to infections, a subcomponent of the humoral immune response. Specifically, the role of a B-cell is to produce antibody molecules that are either cell membrane-bound B-cell receptors or soluble immunoglobulins. The B-cell receptor, expressed by naive and memory B-cells, facilitates the interaction between B cells and foreign antigens. After encountering a foreign antigen, a naive or memory B-cell undergoes activation, leading to its proliferation and transformation into a specialized cell called a plasma cell, which secretes antibodies. Each antibody secreted by a single activated B-cell has a monovalent affinity toward a specific antigen. This means the antibodies bind a single epitope, the part of an antigen recognized by an antibody. The monovalent antibodies secreted from a single B-cell clonal lineage are called monoclonal antibodies. Monoclonal antibodies comprise four polypeptide chains, two identical heavy chains, and two identical light chains. The heavy and light chains are held together by several disulfide bonds that help the polypeptide chains fold to form a Y-shaped tetramer. Biomedical scientists use these epitope-specific antibodies to detect the presence of specific macromolecules and by physicians to treat cancer, autoimmune diseases, and genetic disorders.
Single B-cell sorting is used to isolate individual B-cells to assess how well the secreted antibodies bind a target antigen. Traditional methods of monoclonal antibody development did not involve the isolation and cell culture of single B cells. However, isolating individual B-cells and characterizing the secreted monoclonal antibodies helps scientists capture diverse antibody repertoires improving the probability of discovering rare antibodies with therapeutic potential.
The first step in B-cell isolation involves the immunization of rabbits against a target antigen. This step is important for stimulating the differentiation of naive B-cells into antigen-specific antibody-producing cells. The success of any B-cell isolation project is critically dependent on the quality of the antigen used in the immunization process. For this reason, ProteoGenix can design, synthesize, isolate, and purify each antigen used in our rabbit immunization protocol. This guarantees that specific quality, purity, and concentration standards are achieved for the success of each B-cell isolation project.
Following several rounds of immunization, blood PBMCs, and spleens are collected so antigen-specific B-cells can be isolated. This B-cell isolation step occurs between 6 and 8 weeks after the first rounds of immunization. Single B-cells are sorted by incubating the cells with a biotin-conjugated target antigen followed by incubation with a streptavidin-conjugated fluorophore. The resulting fluorescently labeled antigen-specific B-cells are separated by FACS into individual wells (1 cell per well) of a tissue culture plate. The secreted antibodies are screened to detect antigen binding capacity by ELISA. This process takes between two and three weeks to complete.
Once we identify the monoclonal antibodies with the highest target antigen affinity, we clone the corresponding VH and VL gene segments and transiently express the gene products using our proprietary high-performance XtenCHO cells. As an additional service, ProteoGenix can identify clones with the ability to neutralize specific targets or assess the crossreactivity profile of a specific antibody.
Traditional monoclonal antibody technology involves creating a hybrid cell line by fusing B-cells from immunized mice with an immortal B-cell myeloma cell line. The resulting fused cells are referred to as hybridoma cells because they are a hybrid between a healthy B-cell and a transformed B-cell. Hybridoma cells are isolated and separated into individual wells to assess the antigen-binding potential of the secreted antibodies. The process of B-cell fusion is inefficient. Many B-cells are lost during this process, decreasing the probability of discovering a rare antibody that binds difficult-to-target epitopes. In contrast, our single B-cell screening method maximizes the B-cell isolation and characterization of antibodies secreted from B-cells increasing the probability of discovering rare antibodies that bind a target antigen with precision.
Picking the right team of antibody experts to isolate single B-cells for monoclonal antibody production is critically important given the numerous challenges involved in B-cell isolation. First, the ability to make custom antigens, including conformation-dependent antigens, is critical to success. These antigens are not only necessary for the immunization steps but also for the isolation of antigen-specific B-cells by FACS. The synthesized antigen must be a specific purity and concentration for optimal success. Successful B-cell isolation also requires an array of properly calibrated precision instruments to isolate B-cells and verify antigen binding capacity. In addition, the ability to culture naive and memory B-cells requires well-optimized conditions to promote cell proliferation and maintain cell viability. These parameters alone require years of optimization and expertise. At ProteoGenix, our antibody experts have an average of 25 years of experience in antigen synthesis and antibody development. With 3 therapeutic antibodies on the market and over 30 antibodies in the preclinical and clinical phases of investigation, we know how to make high-performing antibodies for our clients. Book a call with one of our antibody experts to learn how we can help you accelerate your project needs.
Got a question or need a quote? Message us and we'll get back to you 48 hours or less.
Your cart is currently empty.